Remidio Innovative Solutions Pvt. Ltd has been granted US Patent No. 12,611,103 for a 3D eye imaging technology built around a wearable form factor, smart glasses or a VR-style headset in place of a bulky slit lamp or ophthalmoscope.
The device folds more than five separate exams into one. Slit lamp imaging, fundus imaging, and diffused anterior segment imaging, among others, are normally done on separate instruments, this design does all of them, and it can capture images of the eye without pupil dilation, using infrared illumination in place of the bright visible light conventional instruments rely on for a clear view of the back of the eye.
"What used to need a slit lamp, an ophthalmoscope, and several specialised exams can now fit into something worn like a pair of glasses. We’re not just making the equipment smaller, we’re changing where an eye exam can happen. That's the kind of innovation we're always chasing at Remidio - technology that pushes the boundaries care." said Shanmuganathan Nagarajan, AVP of Research and Development at Remidio.
That combination - no dilation, wearable rather than desk-mounted, is what makes the patent relevant to Remidio's broader Oculomics push. The retina is one of the few places in the body where blood vessels can be seen directly, non-invasively, and without radiation. This is why retinal imaging is backed by growing research and clinical validation as the best way to screen for conditions well beyond the eye, cardiovascular disease, diabetes, kidney disease, and neurodegenerative conditions among them – in a fast evolving field of research called Oculomics. A lighter, dilation-free imaging device is a step toward taking that kind of screening out of the specialist's chair and closer to the patient, and eventually, the consumer.
Anand Sivaraman, CEO of Remidio, said "We keep asking the same question, what does it take to bring care closer to the patient, closer to the consumer, even into the home? With Oculomics and a wearable device that consolidates slit lamp and fundus imaging into one unit, without needing a fixed instrument in a specialist's room, is a great way to get there. It's the kind of problem we're always working on at Remidio, rethinking what the future of healthcare needs to look like."
About Remidio -
Today, the human eye is unlocking early insights into systemic health, and Remidio is at the forefront of this transformation. Remidio is a pioneer in AI-driven eye care, leading the shift from care of the eye to healthcare through the eye. As the first company to receive CDSCO approval in India for our adaptive ophthalmic AI, in addition to CE marking in Europe under Class II EU-MDR, we are redefining how diseases like diabetic retinopathy, glaucoma, and AMD are detected early, in close to patient contexts, while remaining confident of extending this to systemic disease detection such as CVD, CKD and liver diseases, in the future.With CE-marked, FDA 510(k)-registered devices, our solutions have screened 16 million+ patients across 55 countries, integrating teleophthalmology and AI for fast, accurate diagnoses. Our innovative retinal imaging solutions ensure precision and efficiency in clinical workflows. Our journey began humbly - thanks to the chance meeting of our founder, with a mission driven ophthalmologist, who brought into focus the need for decentralizing eye testing with simple to use and affordable devices. That conversation, 15 years back, sparked a vision to make high-quality preventive care accessible to all. Guided by innovation, empathy, and a commitment to global impact, our journey is just beginning!
https://www.remidio.com/
IndianWeb2.com is an independent digital media platform for business, entrepreneurship, science, technology, startups, gadgets and climate change news & reviews.
